Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.46 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.46 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HRH1 | P35367 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8532850 | 0.96 | HIF1A (0.58) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Iodide SCHEMBL9549744 | 0.96 | HIF1A (0.58) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9549567 | 0.96 | HIF1A (0.58) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Water SCHEMBL8528580 | 0.96 | HIF1A (0.58) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| SCHEMBL8972950 | 0.90 | HIF1A (0.52) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Bromide SCHEMBL190865 | 0.88 | HTR2A (0.60) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Bicarbonate SCHEMBL8973196 | 0.87 | TSHR (0.52) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Phosphoric Acid SCHEMBL8972371 | 0.87 | HTR2A (0.50) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Bromide SCHEMBL8909571 | 0.86 | HTR2A (0.53) | HIF1AHTR2AHRH1CYP1A2CYP2D6 | |
| Bromide SCHEMBL246032 | 0.86 | HTR2A (0.58) | HIF1AHTR2AHRH1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114097785-A | Polysaccharide-based photothermal sterilization material and application thereof in seed protection and grain storage | 中国科学院化学研究所 | 2022-03-01 | — | — | CN | claimed |
| US-8808403-B2 | Process for solid electrolytic capacitors using polymer slurries | KEMET ELECTRONICS CORPORATION (US) | 2014-08-19 | — | — | US | claimed |
| US-20120201803-A1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-08-09 | — | — | US | claimed |
| WO-2012037362-A2 | PROCESS FOR SOLID ELECTROLYTIC CAPACITORS USING POLYMER SLURRIES | KEMET ELECTRONICS CORPORATION (US) | 2012-03-22 | — | — | WO | claimed |
| US-20120063063-A1 | PROCESS FOR SOLID ELECTROLYTIC CAPACITORS USING POLYMER SLURRIES | KEMET ELECTRONICS CORPORATION (US) | 2012-03-15 | — | — | US | claimed |
| US-7709168-B2 | Phosphonium containing charge transport layer photoconductors | XEROX CORPORATION (US) | 2010-05-04 | — | — | US | claimed |
| US-20090092915-A1 | PHOSPHONIUM CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-20090092914-A1 | PHOSPHONIUM CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0615853-B1 | Recording sheets containing phosphonium compounds | XEROX CORP (US) | 1996-10-16 | — | — | EP | claimed |
| JP-4213319-A | — | — | None | — | — | JP | disclosed |
| WO-2026087965-A1 | COMPOSITION COMPRISING EPOXY RESIN WITH CONSTRAINED AROMATIC RINGS AND PHOTOBASE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025200154-A1 | TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-10-02 | — | — | WO | disclosed |
| CN-114729133-B | Method for forming fiber reinforced composite material and epoxy resin composition used therein | 东丽株式会社 | 2024-09-20 | — | — | CN | disclosed |
| US-4324792-A | SKIN DISORDERS, HAY FEVER, ASTHMA | GLAXO GROUP LIMITED (GB) | 1982-04-13 | — | — | US | disclosed |
| WO-1981001407-A1 | NOVEL HALOPHENYL-PYRIDYL-ALLYLAMINE DERIVATIVES | ASTRA LAEKEMEDEL AB (SE) | 1981-05-28 | — | — | WO | disclosed |
| EP-0029420-A1 | Novel halophenyl-pyridyl-allylamine derivatives, processes and intermediates as well as pharmaceutical preparations thereof | Astra Läkemedel Aktiebolag (SE) | 1981-05-27 | — | — | EP | disclosed |
| WO-1979000023-A1 | A NOVEL PROCESS FOR PREPARATION OF A THERAPEUTICALLY ACTIVE PYRIDINE COMPOUND | ASTRA LAEKEMEDEL AB (SE) | 1979-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201803-A1 | 3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID | XDH, NLRP3, ASIC3 | CHRM2 3297/4885CHRM4 2637/4885CHRM5 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.